[Form 4] Harmony Biosciences Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Sandip Kapadia, Chief Financial Officer of Harmony Biosciences Holdings, Inc. (HRMY), reported transactions dated 09/30/2025. He acquired 45,000 shares upon vesting of restricted stock units (RSUs) granted on 10/04/2023, and a portion of those shares were withheld to satisfy income tax withholdings as noted. Separately, he disposed of 24,039 shares at a price of $27.56 per share, leaving him with 20,961 shares beneficially owned after the sale. The RSUs vest on a schedule: 40% vested on 09/30/2024, and 30% vest on each of 09/30/2025 and 09/30/2026. The filing was signed by an attorney-in-fact on 10/02/2025.

Positive

• 45,000 RSUs converted to common stock on 09/30/2025 per the grant schedule
• RSU vesting schedule is disclosed: 40% (09/30/2024), 30% (09/30/2025), 30% (09/30/2026)

Negative

• 24,039 shares sold at $27.56 on 09/30/2025, reducing beneficial ownership to 20,961 shares
• Shares withheld for tax withholding following RSU vesting (amount withheld not separately quantified beyond the net ownership figures)

Insights

Corporate Insider Transactions Analyst

Insider received RSUs and executed a partial sale on 09/30/2025.

The filing shows a scheduled vesting event converting 45,000 RSUs into common shares, reflecting the compensation schedule established on 10/04/2023. A portion of shares was withheld to cover tax withholding obligations, a common practice on RSU vesting.

The reporting person then sold 24,039 shares at $27.56, resulting in 20,961 shares remaining beneficially owned. These are explicit, non‑speculative facts from the Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Kapadia Sandip

(Last) (First) (Middle)

C/O HARMONY BIOSCIENCES HOLDINGS, INC.

630 W GERMANTOWN PIKE, SUITE 215

(Street)

PLYMOUTH MEETING PA 19462

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Harmony Biosciences Holdings, Inc. [ HRMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2025		M		45,000	A	$0	45,000	D
Common Stock(1)	09/30/2025		F		24,039	D	$27.56	20,961	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	09/30/2025		M			45,000	(2)	(2)	Common Stock	45,000	$0	45,000	D

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date.

2. The restricted stock units were granted on October 4, 2023. 40% of the restricted stock units shall vest on September 30, 2024 and 30% shall vest on each of September 30, 2025 and September 30, 2026. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.

	/s/ Christian Ulrich, Attorney-in-Fact	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did HRMY CFO Sandip Kapadia report on Form 4?

He reported acquisition of 45,000 shares from RSU vesting on 09/30/2025 and a sale of 24,039 shares at $27.56 on the same date.

How many HRMY shares does Sandip Kapadia beneficially own after the reported transactions?

The Form 4 shows he beneficially owns 20,961 shares following the reported transactions.

What was the RSU grant and vesting schedule for Kapadia's awards?

The RSUs were granted on 10/04/2023: 40% vested on 09/30/2024, and 30% vest on each of 09/30/2025 and 09/30/2026.

Was any price paid for the RSU-converted shares?

The RSU conversion to shares shows an acquisition code with $0 price, indicating shares were received upon vesting rather than purchased.

Who signed the Form 4 filing for Kapadia?

The Form 4 was signed by Christian Ulrich, Attorney-in-Fact on 10/02/2025.